NetraMark

What NetraMark does

NetraMark (legal entity NetraMark Health Inc., formerly Nurosene) is a Toronto-based, publicly traded AI/pharma-tech company founded in 2016 by Dr. Joseph Geraci. It sells AI-powered clinical-trial analytics to pharmaceutical and biotech sponsors, helping them analyze Phase 2 and Phase 3 trial data to identify responder subpopulations, optimize patient stratification, model dose-response, characterize placebo response, and design smaller, more efficient late-stage studies. Primary verticals are CNS/neuroscience (depression, schizophrenia, Alzheimer's, psychedelics), oncology, and rare disease.

The core product is NetraAI (now version 2.0), a proprietary analytics platform built on "Attractor AI," a topology-based long-range attractor algorithm combined with dynamical-systems modeling and evolutionary long-range memory feature selection. The architecture is designed to extract high-effect-size patient subgroups from the small, complex, multimodal datasets typical of clinical trials—structured clinical variables, genetic/epigenetic data, MRI/neuroimaging, and digital markers—where conventional large-data ML approaches underperform. Outputs are positioned as fully explainable, and the platform is extended by NetraGPT (LLM integration for trial de-risking) and the Treatment Attitude Profile (TAP) scale for placebo-response analysis. Published results cite a 0.32 AUC improvement over traditional ML in a Phase II ketamine depression trial and a 95%-accuracy/100%-specificity MRI responder model.

The business model is project-based professional services: NetraMark signs Master Service Agreements and per-project commercial contracts with global biopharma sponsors, supplemented by a CRO channel partnership with Worldwide Clinical Trials and research collaborations with FMP, CAMH, and NIMH. Pricing is undisclosed and negotiated per engagement. As of Q2 FY2026 (March 31, 2026) the company reported approximately C$3.09M in aggregate signed contract value with roughly C$2.96M remaining in backlog, and had recognized C$129,000 of revenue in Q1 FY2026. Go-to-market is enterprise field sales, supported by a science-driven marketing engine of peer-reviewed publications, conference posters, and FDA engagement.

Name

NetraMark

Legal name

NetraMark Health Inc.

Website

https://netramark.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

NetraMark is a Toronto-based, publicly traded (TSX: AIAI) AI pharma-tech firm whose NetraAI platform analyzes clinical-trial data for biopharma sponsors, identifying responder subpopulations and optimizing Phase 2/3 trial design across CNS, oncology, and rare-disease programs.

Ownership category

akta.pro rank

Product category

Clinical Trial Analytics Software

NAICS

Computer Systems Design Services (541512)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO)

Keywords

• Clinical trial analytics
• AI patient stratification
• Pharmacogenomics platform
• Precision oncology analytics
• Predictive trial enrichment

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Clinical Trial Analytics Services: NetraMark provides AI-powered analytics services to pharmaceutical companies for analyzing clinical trial data. Services include patient subpopulation identification, treatment efficacy analysis, dose-response modeling, and trial design optimization. Revenue is generated through project-based contracts with global biopharma companies across Phase 2 and Phase 3 programs.
2. Strategic Partnership Analytics: Analytics engagements through strategic partnerships with CROs like Worldwide Clinical Trials and research collaborations with institutions like CAMH, NIMH, and Fondazione per la Medicina Personalizzata.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

NetraMark develops and licenses NetraAI, an AI-powered clinical trial optimization platform that applies proprietary Attractor AI algorithms to analyze multimodal patient data (clinical variables, imaging, genetic/epigenetic data) from Phase II/III trials. The platform identifies treatment-responsive patient subpopulations, predicts responders and placebo responders, and informs trial design and inclusion/exclusion criteria. It is delivered to global pharmaceutical and biotech sponsors through negotiated project-based analytics contracts and CRO channel partnerships.

Product overview

NetraMark offers a unified AI-powered clinical trial optimization platform centered on NetraAI. The platform comprises the core NetraAI engine (including version 2.0), extended by NetraGPT for LLM integration and the Treatment Attitude Profile (TAP) Scale for placebo response analysis. NetraAI uses proprietary Attractor AI algorithms to analyze multimodal clinical trial data, identifying patient subpopulations, predicting treatment response, and optimizing trial design through explainable AI approaches.

Differentiator

Problem solved

Functional benefit

Products and services

• NetraAI Proprietary AI-powered precision analytics platform for clinical trial optimization. Uses Attractor AI (a topology-based long-range attractor algorithm) to parse patient datasets into strongly related subpopulations, enabling predictive enrichment, patient stratification, and identification of treatment responders, placebo responders, and causal variables. Sold to global pharmaceutical and biotech sponsors through project-based enterprise contracts and CRO channel partnerships.
• NetraGPT Extends NetraAI by integrating large language model capabilities for clinical trial de-risking. Combines LLMs with the core Attractor AI technology to generate insights and natural-language interpretations from clinical trial data. Sold as part of NetraMark's clinical trial analytics offering to pharmaceutical sponsors.
• Treatment Attitude Profile (TAP) Scale A novel clinical assessment scale for placebo response persona discovery using Attractor AI technologies. Enables clinical trial patient enrichment by identifying placebo response patterns in trial participants, addressing the placebo-response challenge that dilutes treatment effects in CNS and other trials.

Quantifiable outcome

• NetraAI identified a 10-clinical variable model that improved predictive AUC by 0.32 over traditional machine learning in a Phase II ketamine trial for treatment-resistant depression.
• +2 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Fondazione per la Medicina Personalizzata (FMP)coreStrategic or Co-development Partner · 25 March 2026Strategic research collaboration to analyze the landmark ROME Phase II oncology trial dataset using NetraMark's proprietary NetraAI platform. The collaboration aims to identify Model-Derived Subgroups and clinically actionable patient subpopulations from 400 patients with advanced solid tumors that may inform future precision-oncology strategies and clinical trial design. The ROME trial was reported in Nature Medicine.
• CAMH (Centre for Addiction and Mental Health)coreStrategic or Co-development Partner · 16 December 2025Research collaboration involving deployment of NetraAI for analyzing genetic and epigenetic data related to psychiatric disorders (schizophrenia and depression). The project aims to identify biological subtypes and improve personalized treatment strategies with potential enhancements to clinical trial outcomes.
• Asklepion PharmaceuticalsminorStrategic or Co-development Partner · 5 August 2025Contract to utilize NetraMark technology in Phase III Pediatric Cardiac Study, expanding platform application to pediatric cardiology trials.
• AlgoTxminorStrategic or Co-development Partner · 28 July 2025Contract to enhance clinical trial design for ATX01 using NetraAI platform to optimize patient stratification and trial outcomes.
• Worldwide Clinical TrialscoreStrategic or Co-development Partner · 3 April 2025Strategic agreement to transform clinical trial design with AI-powered insights. Worldwide Clinical Trials is a leading global CRO operating in more than 60 countries with over 3,600 employees. The partnership enables integration of NetraAI capabilities into Worldwide's clinical research services, extending market reach through the CRO's established pharma client relationships.
• Ontario Brain InstituteminorStrategic or Co-development Partner · 25 February 2025Partnership to advance AI-powered neuroanalytics for major depression research. Collaboration involves applying graph theory imaging tools and identifying patient subgroups for depression care improvement.
• NIMH (National Institute of Mental Health)coreStrategic or Co-development Partner · 10 June 2024Collaboration agreement to analyze clinical trial data on the use of ketamine in psychiatric disorders. The partnership brings federal research validation to NetraAI's capabilities in CNS clinical trial optimization.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Medidata (Dassault Systèmes): Medidata is the dominant clinical trial technology platform (EDC, CTMS, eCOA, RTSM, analytics) used by most global pharma. It overlaps with NetraMark as a competitor in trial analytics and patient stratification, but operates as a broad platform incumbent rather than a focused AI subpopulation discovery tool.
• Veeva Systems: Veeva provides cloud software for life sciences including CTMS, EDC, and clinical data management. It competes with NetraMark for pharma trial technology budgets and increasingly incorporates AI capabilities into its platform, posing a bundling threat to standalone AI analytics vendors.
• IQVIA: IQVIA is the largest CRO and clinical data analytics provider globally, with extensive AI-driven real-world evidence and trial design capabilities. It competes both as a CRO distribution channel alternative to Worldwide and as a direct analytics provider for pharma trial optimization.

Direct peers

• Saama Technologies: Saama is an AI-focused clinical trial analytics platform that helps pharma with patient stratification, site selection, and operational analytics. It is one of the most direct competitive analogs to NetraAI in applying AI specifically to clinical trial optimization.
• Deep 6 AI: Deep 6 AI uses AI to mine medical records for clinical trial patient recruitment and cohort identification. While focused on recruitment rather than in-trial analytics, it shares NetraMark's positioning of AI as a tool to address patient heterogeneity in trials.
• Cytel: Cytel provides statistical and biostatistics software and services for clinical trial design, including adaptive trials and synthetic control arms. It overlaps with NetraMark's biostatistical and trial-design optimization value proposition for pharma clinical teams.

Emerging players

• Unlearn.AI: Unlearn.AI uses AI-generated digital twins to power smaller, faster clinical trials in CNS and other therapeutic areas. It competes in the same AI-for-trial-optimization category as NetraMark with a different technical approach (prognostic digital twins vs. attractor-based subpopulation discovery).
• Owkin: Owkin applies AI to clinical research and drug development, including patient stratification and biomarker discovery across pharma and academic partners. It shares NetraMark's positioning in AI-driven precision medicine for trial optimization, though at a significantly larger scale.
• GNS Healthcare: GNS Healthcare applies causal AI and simulation to oncology and immunology trial design and patient stratification. It is comparable to NetraMark in using advanced AI (including dynamical-systems approaches) to uncover patient subpopulations for pharma R&D.
• Trial Library: Trial Library uses AI to match patients to clinical trials and accelerate oncology trial recruitment. It is adjacent to NetraMark's patient stratification capabilities with a focus on feasibility and matching rather than post-hoc in-trial subpopulation analytics.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/netramark

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NetraMark